Skip to main content

Table 1 Risk Evaluations for Prostate Cancer

From: Development of a real-time clinical decision support system upon the web mvc-based architecture for prostate cancer treatment

Risk group

Risk factors

Risk (a, b, c)%

Low

T1c or T2a and PSA <= 10 ng/ml and Gleason score <= 6

(< 25, 85, 83)

Intermediate

T2b or Gleason score = 7 or PSA > 10 and <= 20 ng/ml

(25-50, 60, 46)

High

T2c or PSA > 20 ng/ml or Gleason score >= 8

(> 50, 30, 29)

  1. a. Post-therapy PSA failure at 5 yrs; b. PSA failure-free survival at 5 yrs;
  2. c. PSA failure-free survival at 10 yrs
Back to article page